QuidelOrtho

Last updated
QuidelOrtho Corporation
Company type Public
IndustryPharmaceutical Industry
Founded1979;45 years ago (1979)
FoundersDr. David H. Katz, M.D.
Headquarters San Diego, California, U.S.
Key people
Michael Iskra, Interim CEO
Joseph M. Busky, CFO
[1]
ProductsDiagnostic healthcare manufacturer
RevenueIncrease2.svg $534.2 Million(2019) [2]
Number of employees
6,500
Website quidelortho.com

QuidelOrtho Corporation is a major American manufacturer of diagnostic healthcare products that are sold worldwide. [3]

Contents

On May 8, 2020 the U.S. Food and Drug Administration (FDA) has issued the first emergency use authorization (EUA) for a COVID-19 antigen test, a new category of tests for use in the ongoing pandemic. These diagnostic tests quickly detect fragments of proteins found on or within the virus by testing samples collected from the nasal cavity using swabs. [4]

History

Quidel was founded by Dr. David H. Katz, M.D., commencing operations in 1981 and launched its first products in 1984. Quidel Corporation was formed in 1991 when Quidel and Monoclonal Antibodies merged. [5]

In 1988, Dr. Katz, a founder and chief scientific officer at Quidel, resigned to devote his energies to the Medical Biology Institute, a nonprofit research group in La Jolla, California that is closely allied with Quidel. [6]

On June 18, 1997 Quidel settled a lawsuit with Becton Dickinson. Quidel had been accused of infringing patents on Becton's strep and chlamydia products. Quidel agreed to buy a product license and pay royalties on its product sales. [7]

In 1999, Quidel acquired Metra Biosystems, Inc.to participate in bone health assessment. [8] In 2000, Quidel acquired Litmus Concepts, Inc., a privately held in vitro diagnostic company. [9]

In February 2004, Inverness Medical Innovations sued Quidel for patent infringement. That same month, Quidel countersued against Inverness. [10]

In 2010, Quidel acquired Diagnostic Hybrids, Inc. a privately held in vitro diagnostic company. [11] In 2013, Quidel acquired BioHelix Corporation, established in 2004, [12] and was to pay $10 million to the BioHelix shareholders. [13]

In May 2020, Quidel’s Sofia 2 SARS Antigen FIA has become the first COVID-19 antigen test to be granted Emergency Use Authorization (EUA) by the FDA, [4] [14] approved by FDA director in charge of authorizing test EUAs, Tim Stenzel, who is also Quidel’s former Chief Science Officer who, while leading Quidel, oversaw the initial launch of the Sofia instrument. [15]

In December 2021, Quidel announced it would acquire Ortho Clinical Diagnostics Holdings for $6 billion in cash and stock, increasing the range of COVID-19 antigen and antibody tests the business is able to offer. [16]

In February 2024, CEO Douglas Bryant was fired, being replaced by Michael Iskra as interim CEO. [17]

List of mergers and acquisitions

The following is an illustration of the company's major mergers and acquisitions and historical predecessors:

  • Quidel(Est. 1991)
    • Metra Biosystems, Inc. (Acq 1999)
    • Litmus Concepts, Inc. (Acq 2000)
    • Diagnostic Hybrids, Inc. (Acq 2010)
    • BioHelix Corporation (Acq 2013)
    • Ortho Clinical Diagnostics (Acq 2021)

Expertise

Since its merger, Quidel has expanded its product base through internal development and acquisition with a focus on increasing its research and development efforts to accelerate the rate of new product introductions.[ citation needed ]

Quidel's core competencies and capabilities include immunoassay development, automated manufacturing, monoclonal antibody characterization and development, and molecular assay development.

Products

Quidel's current products fall generally into these categories: (1) lateral flow, where it focuses on infectious disease and reproductive health; (2) direct fluorescent antibodies (DFA), with expertise in infectious disease and virology; (3) micro-titer production, with a focus on bone and complement pathway markets; (4) fluorescent immunoassay products (Sofia); and (5) molecular diagnostic products.

These products include assays such as QuickVue, Thyretain and the new Sofia and AmpliVue brands, which focus on diagnosing influenza, thyroid disease, and many other diseases, and can improve the healthcare quality of hospitals. [18]

During 2011, the US Food and Drug Administration (FDA) and the European Conformity Mark provided Quidel with 510(k) clearance for selling Sofia Analyzer, and another 510(k) clearance for the Quidel Molecular hMPV Assay. [19]

Related Research Articles

<span class="mw-page-title-main">Diagnosis of HIV/AIDS</span> Immunological test

HIV tests are used to detect the presence of the human immunodeficiency virus (HIV), the virus that causes acquired immunodeficiency syndrome (AIDS), in serum, saliva, or urine. Such tests may detect antibodies, antigens, or RNA.

Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Green Oaks, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

<span class="mw-page-title-main">Roche</span> Swiss multinational healthcare company

F. Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational holding healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel. Roche is the fifth-largest pharmaceutical company in the world by revenue and the leading provider of cancer treatments globally. In 2023, the company’s seat in Forbes Global 2000 was 76.

<span class="mw-page-title-main">PerkinElmer</span> American corporation focused on life science research

PerkinElmer, Inc., previously styled Perkin-Elmer, is an American global corporation that was founded in 1937 and originally focused on precision optics. Over the years it went into and out of several different businesses via acquisitions and divestitures; these included defense products, semiconductors, computer systems, and others. By the 21st century, PerkinElmer was focused in the business areas of diagnostics, life science research, food, environmental and industrial testing. Its capabilities include detection, imaging, informatics, and service. It produced analytical instruments, genetic testing and diagnostic tools, medical imaging components, software, instruments, and consumables for multiple end markets. PerkinElmer was part of the S&P 500 Index and operated in 190 countries.

Heterophile antibodies are antibodies induced by external antigens.

Zimmer Biomet Holdings, Inc. is a publicly traded medical device company. It was founded in 1927 to produce aluminum splints. The firm is headquartered in Warsaw, Indiana, where it is part of the medical devices business cluster.

<span class="mw-page-title-main">Thermo Fisher Scientific</span> Provisioner of scientific consumables, equipment, and services

Thermo Fisher Scientific Inc. is an American supplier of analytical instruments, life sciences solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services. Based in Waltham, Massachusetts, Thermo Fisher was formed through the merger of Thermo Electron and Fisher Scientific in 2006. Thermo Fisher Scientific has acquired other reagent, consumable, instrumentation, and service providers, including Life Technologies Corporation (2013), Alfa Aesar (2015), Affymetrix (2016), FEI Company (2016), BD Advanced Bioprocessing (2018), and PPD (2021).

Ortho Clinical Diagnostics was an in vitro diagnostics company that made products and diagnostic equipment for blood testing. Ortho served two primary industries in the medical field: clinical laboratories, by producing platforms and assays that test for a variety of diseases, conditions, and substances; and immunohematology, by providing the means to ensure blood transfusion recipients receive appropriate and compatible blood.
Johnson and Johnson acquired Eastman Kodak's Clinical Diagnostics Division in 1994, which was then merged with Ortho Diagnostic Systems in 1997. QuidelOrtho's global corporate offices are in Raritan, New Jersey, while their global research and development center is in Rochester, New York.

Laboratory Corporation of America Holdings, more commonly known as Labcorp, is an American healthcare company headquartered in Burlington, North Carolina. It operates one of the largest clinical laboratory networks in the world, with a United States network of 36 primary laboratories. Before a merger with National Health Laboratory in 1995, the company operated under the name Roche BioMedical. Labcorp performs its largest volume of specialty testing at its Center for Esoteric Testing in Burlington, North Carolina, where the company is headquartered. As of 2018, Labcorp processes 2.5 million lab tests weekly.

An Emergency Use Authorization (EUA) in the United States is an authorization granted to the Food and Drug Administration (FDA) under sections of the Federal Food, Drug, and Cosmetic Act as added to and amended by various Acts of Congress, including by the Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 (PAHPRA), as codified by 21 U.S.C. § 360bbb-3, to allow the use of a drug prior to approval. It does not constitute approval of the drug in the full statutory meaning of the term, but instead authorizes the FDA to facilitate availability of an unapproved product, or an unapproved use of an approved product, during a declared state of emergency from one of several agencies or of a "material threat" by the Secretary of Homeland Security.

DiaSorin is an Italian multinational biotechnology company that produces and markets in vitro diagnostics reagent kits used in immunodiagnostics and molecular diagnostics and since July 2021, it is also active in the Life Science business. The group was founded in 2000 and is headquartered in Saluggia, Italy. Its production is at several plants located in Europe and the United States: Saluggia and Gerenzano (Italy), Dietzenbach (Germany), Stillwater, Minnesota (US), Dartford (UK). Following the acquisition of Luminex, the company acquired five additional production plants located in the United States and in Canada (Toronto). The company is a constituent of the FTSE MIB index.

Viral disease testing is the use of a variety of testing techniques for a variety of purposes, including diagnosing conditions, assessing immunity and understanding disease prevalence. The primary approaches include DNA/RNA tests, serological tests and antigen tests.

<span class="mw-page-title-main">Casirivimab/imdevimab</span> Antiviral combination medication

Casirivimab/imdevimab, sold under the brand name REGEN‑COV among others, is a combination medicine used for the treatment and prevention of COVID‑19. It consists of two human monoclonal antibodies, casirivimab and imdevimab that must be mixed together and administered as an infusion or subcutaneous injection. The combination of two antibodies is intended to prevent mutational escape. It is also available as a co-formulated product. It was developed by the American biotechnology company Regeneron Pharmaceuticals.

Bamlanivimab is a monoclonal antibody developed by AbCellera Biologics and Eli Lilly as a treatment for COVID-19. The medication was granted an emergency use authorization (EUA) by the US Food and Drug Administration (FDA) in November 2020, and the EUA was revoked in April 2021.

Bamlanivimab/etesevimab is a combination of two monoclonal antibodies, bamlanivimab and etesevimab, administered together via intravenous infusion as a treatment for COVID-19. Both types of antibody target the surface spike protein of SARS‑CoV‑2.

<span class="mw-page-title-main">COVID-19 rapid antigen test</span> Diagnostic test for a SARS-CoV-2 infection

COVID-19 rapid antigen tests or RATs, also frequently called COVID-19 lateral flow tests or LFTs, are rapid antigen tests used to detect SARS-CoV-2 infection (COVID-19). They are quick to implement with minimal training, cost a fraction of other forms of COVID-19 testing, and give users a result within 5–30 minutes. RATs have been used in several countries as part of mass testing or population-wide screening approaches. Many RATs can be used for self-testing, in which an individual "collects their own specimen… and interpret[s] their test result themselves".

<span class="mw-page-title-main">Sotrovimab</span> Monoclonal antibody

Sotrovimab, sold under the brand name Xevudy, is a human neutralizing monoclonal antibody with activity against severe acute respiratory syndrome coronavirus 2, known as SARS-CoV-2. It was developed by GlaxoSmithKline and Vir Biotechnology, Inc. Sotrovimab is designed to attach to the spike protein of SARS-CoV-2.

Seegene, Inc is a Korean manufacturer of in vitro diagnostic (IVD) products, particularly molecular diagnostics. Its portfolio includes a range of assays and screening products for sepsis, respiratory diseases such as influenza and respiratory syncytial virus, as well as sexually transmitted infections (STIs). It was founded in 2000. In early 2020, it began developing and distributing a range of tests for SARS-CoV-2, the virus that causes COVID-19.

References

  1. ↑ Plunkett, Jack W. (1 October 2008). Plunkett's Health Care Industry Almanac 2009 (E-Book): Health Care Industry Market Research, Statistics, Trends and Leading Companies. Plunkett Research, Ltd. p. 598. ISBN   9781593921323.
  2. ↑ "Quidel Reports Fourth Quarter and Full Year 2019 Financial Results".
  3. ↑ "Quidel Corporation Profile Dunn Bradstreet".
  4. 1 2 Commissioner of Food and Drugs - Food and Drug Administration, Stephen M. Hahn M.D. (May 9, 2020). "Coronavirus (COVID-19) Update: FDA Authorizes First Antigen Test to Help in the Rapid Detection of the Virus that Causes COVID-19 in Patients". FDA. Retrieved 11 May 2020.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  5. ↑ Mamo, Laura (August 14, 2007). Queering Reproduction: Achieving Pregnancy in the Age of Technoscience. Duke University Press. p. 266. ISBN   9780822390220.
  6. ↑ Kraul, Chris, "The founder and chairman of Quidel ... resigns", The Los Angeles Times, March 30, 1988.
  7. ↑ "Quidel Settlement". thepharmaletter. June 18, 1997. Retrieved 17 January 2017.
  8. ↑ "Quidel Corporation Completes Acquisition of Metra Biosystems;".
  9. ↑ "QUIDEL CORPORATION COMPLETES ACQUISITION OF LITMUS CONCEPTS".
  10. ↑ Meland, Marius (February 23, 2004). "Quidel Strikes Back With Patent Lawsuits Against Rivals". Law360. Retrieved 17 January 2017.
  11. ↑ "Quidel Corporation (QDEL) to Buy Diagnostic Hybrids, Inc. for $130 Million".
  12. ↑ "QDEL - Google Search". www.google.com.
  13. ↑ "Quidel Completes Acquisition of BioHelix Corporation". article.wn.com.
  14. ↑ "Quidel's Sofia 2 SARS Antigen FIA Becomes First COVID-19 Antigen Test to Secure FDA Emergency Use Authorization". 11 May 2020.
  15. ↑ "Here's Why Rapid COVID Tests Are So Expensive and Hard to Find".
  16. ↑ "Quidel to buy Ortho Clinical for $6 bln to boost diagnostics portfolio | Reuters". Reuters. 23 December 2021.
  17. ↑ "QuidelOrtho Board Fires CEO Douglas Bryant, Postpones Investor Day } MarketWatch". MarketWatch. 21 February 2024.
  18. ↑ "Quidel to Present at Cowen 34th Annual Health Care Conference". finance.yahoo.com. 18 February 2014.
  19. ↑ "Quidel Corporation QDEL.O". Reuters.com.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.